Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4  (01-2012)

Period of time： 2012年4期

Publisher： Bentham Science Publishers

Founded in： 2001

Total resources： 51

E-ISSN： 2212-3873|12|4

ISSN： 1871-5303

Subject： R9 Pharmacy

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4

Menu

Acknowledgement

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. i-i

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Editorial [Hot Topic: Vasoactive Intestinal Peptide (VIP): Historic Perspective and Future Potential]

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 303-307

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

VIP as a Potential Therapeutic Agent in Gram Negative Sepsis

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 308-315

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

VIP in Inflammatory Bowel Disease: State of the Art

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 316-322

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

VIP in Neurological Diseases: More Than A Neuropeptide

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 323-332

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Potential Applications of Vasoactive Intestinal Peptide-Based Therapies on Transplantation

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 333-343

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 344-350

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Oxidative Stress in Atherosclerosis Development: The Central Role of LDL and Oxidative Burst

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 351-360

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Role of the Gut Microbiota in Age-Related Chronic Inflammation

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 361-367

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders),volume 12,issue 4 , Vol. 12, Iss. 4, 2012-12 , pp. 368-376

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Previous 1 2 Next Display item(s) per page Total 11 item(s)